Friday, December 22, 2006

GlaxoSmithKline Withdraws Patent Application for Asthma

GSK has withdrawn its patent application for asthma drug covering combination of fluticasone and salmeterol following pre-grant opposition by Cipla. This is the second time that GSK has withdrawn its patent application. In March, it was forced to withdraw its patent application on fixed dose combination of zidovudine and lamivudine. Dr. Gopakumar G. Nair, IPR consultant representing Cipla said that “the application was withdrawn by Glaxo, based on the evidence which was overwhelming.” Dr. Nair is pharmaceutical patent expert and CEO of Mumbai-based Patent Consultancy firm Gopakumar Nair Associates and explicitly dealing with pre-grant, post-grant and other patent related matters.

No comments:

Post a Comment